MCID: TRC022
MIFTS: 41

Tricuspid Valve Insufficiency

Categories: Cardiovascular diseases

Aliases & Classifications for Tricuspid Valve Insufficiency

MalaCards integrated aliases for Tricuspid Valve Insufficiency:

Name: Tricuspid Valve Insufficiency 12 45 15 74
Tricuspid Regurgitation 12 30 56 6 15
Tricuspid Valve Regurgitation 12
Tricuspid Incompetence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4080
MeSH 45 D014262
UMLS 74 C0040961

Summaries for Tricuspid Valve Insufficiency

Disease Ontology : 12 A tricuspid valve disease that is characterized by failure of the heart's tricuspid valve to close properly during systole. As a result, with each heart beat, blood is pumped out from the right side of the heart in the opposite direction to normal.

MalaCards based summary : Tricuspid Valve Insufficiency, also known as tricuspid regurgitation, is related to mitral valve insufficiency and constrictive pericarditis. An important gene associated with Tricuspid Valve Insufficiency is PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11). The drugs Amiodarone and Propafenone have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and testes.

Related Diseases for Tricuspid Valve Insufficiency

Diseases in the Tricuspid Valve Disease family:

Tricuspid Valve Insufficiency

Diseases related to Tricuspid Valve Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 mitral valve insufficiency 31.2 FBN1 NPPB
2 constrictive pericarditis 30.9 ALB NPPB
3 tetralogy of fallot 30.7 FBN1 NPPB PTPN11
4 heart disease 30.6 ALB NPPB PTPN11 ZIC3
5 heart valve disease 30.6 ARSE FBN1 NPPB
6 pulmonary hypertension, primary, 1 30.4 FBN1 NPPB
7 patent ductus arteriosus 1 30.4 NPPB PTPN11
8 tricuspid valve stenosis 30.4 ARSE CA6 FBN1
9 aortic valve insufficiency 30.3 FBN1 NPPB
10 pulmonary valve insufficiency 30.2 BLVRA NPPB
11 pulmonic stenosis 30.2 PTPN11 ZIC3
12 third-degree atrioventricular block 30.1 NPPB SLC35B2
13 tricuspid valve disease 29.5 ARSE FBN1 MC3R NPPB ZIC3
14 mungan syndrome 11.4
15 rere-related disorders 10.7
16 atrial fibrillation 10.5
17 mitral valve stenosis 10.5
18 endocarditis 10.5
19 varicose veins 10.4
20 sickle cell disease 10.4
21 congestive heart failure 10.4
22 pericarditis 10.4
23 atrioventricular block 10.3
24 patent foramen ovale 10.3
25 toxic myocarditis 10.3 NPPB ZIC3
26 thalassemia 10.3
27 chylothorax, congenital 10.3 ALB PTPN11
28 syndrome of inappropriate antidiuretic hormone 10.2 ALB NPPB
29 noma 10.2 ALB PTPN11
30 down syndrome 10.2
31 rheumatic heart disease 10.2
32 hyperthyroidism 10.2
33 pulmonary embolism 10.2
34 thyroid crisis 10.2 ALB ZIC3
35 renal hypertension 10.2 ALB NPPB
36 pericardium disease 10.2 ALB ZIC3
37 graves disease 1 10.2
38 sickle cell anemia 10.2
39 kawasaki disease 10.2
40 acute myocardial infarction 10.2
41 dilated cardiomyopathy 10.2
42 cardiogenic shock 10.2
43 transposition of the great arteries 10.1
44 atrial standstill 1 10.1
45 cardiac valvular defect, developmental 10.1
46 orthostatic intolerance 10.1
47 beta-thalassemia 10.1
48 arteriovenous fistula 10.1
49 venous insufficiency 10.1
50 hypertrophic cardiomyopathy 10.1

Graphical network of the top 20 diseases related to Tricuspid Valve Insufficiency:



Diseases related to Tricuspid Valve Insufficiency

Symptoms & Phenotypes for Tricuspid Valve Insufficiency

Drugs & Therapeutics for Tricuspid Valve Insufficiency

Drugs for Tricuspid Valve Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
2
Propafenone Approved Phase 4 54063-53-5 4932
3
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
4
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Not Applicable 68-04-2
5
Tolvaptan Approved Phase 4 150683-30-0 216237
6
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
7
Angiotensin II Approved, Investigational Phase 4,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
8
Losartan Approved Phase 4 114798-26-4 3961
9
Chlorthalidone Approved Phase 4 77-36-1 2732
10
Amlodipine Approved Phase 4 88150-42-9 2162
11
Trimetazidine Approved, Investigational Phase 4 5011-34-7
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 77-92-9 311
13
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
14 Kava Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 9000-38-8
15 Adrenergic beta-Antagonists Phase 4
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Cytochrome P-450 CYP3A Inhibitors Phase 4
18 Cytochrome P-450 Enzyme Inhibitors Phase 4
19 Sodium Channel Blockers Phase 4
20 Anti-Arrhythmia Agents Phase 4
21 Potassium Channel Blockers Phase 4
22 Adrenergic Agents Phase 4,Phase 1
23 Sympatholytics Phase 4
24 Vasodilator Agents Phase 4,Phase 2,Phase 1,Not Applicable
25 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
26 Diuretics, Potassium Sparing Phase 4
27 Adrenergic Antagonists Phase 4
28 Neurotransmitter Agents Phase 4,Phase 1
29 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
30 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
31 Autonomic Agents Phase 4,Phase 1
32 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
33 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2,Not Applicable
34 Sildenafil Citrate Phase 4,Phase 2,Not Applicable 171599-83-0
35 Citrate Phase 4,Phase 2,Not Applicable
36 Natriuretic Agents Phase 4
37 Vasopressins Phase 4
38 Hormones Phase 4
39 Torsemide Phase 4
40 Arginine Vasopressin Phase 4
41 Antihypertensive Agents Phase 4,Phase 3,Phase 2
42 diuretics Phase 4,Not Applicable
43 Antidiuretic Hormone Receptor Antagonists Phase 4
44 Sodium Potassium Chloride Symporter Inhibitors Phase 4
45 Anticoagulants Phase 4
46 Chelating Agents Phase 4
47 Calcium, Dietary Phase 4
48 Angiotensin Receptor Antagonists Phase 4,Phase 2
49 Angiotensinogen Phase 4,Phase 2
50 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 124)
# Name Status NCT ID Phase Drugs
1 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
2 Tricuspid Regurgitation Study Completed NCT01093001 Phase 4
3 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
4 Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction Completed NCT02133352 Phase 4 Ranolazine
5 Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease Completed NCT00862043 Phase 4 Sildenafil Citrate;Placebo
6 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension Completed NCT01642407 Phase 4 Sildenafil
7 Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER) Recruiting NCT02339974 Phase 4
8 Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Recruiting NCT03666351 Phase 4 Amlodipine 5mg;Losartan;Losartan and Amlodipine;Amlodipine/Losartan/Chlorthalidone;current treatment
9 Cardiac Metabolic Modulator Treatment for Improvement of Diastolic Function in Patients With Coronary Heart Disease Not yet recruiting NCT03887013 Phase 4 Trimetazidine
10 Minimally Invasive Transthoracic Device Closure in Perimembranous Ventricular Septal Defect Unknown status NCT02644330 Phase 2, Phase 3
11 Comparison of Two Types of Shunts in Infants With Single Ventricle Defect Undergoing Staged Reconstruction--Pediatric Heart Network Completed NCT00115934 Phase 3
12 Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) Completed NCT00147199 Phase 3 Inhaled treprostinil;Placebo inhalation solution
13 Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride Recruiting NCT03270514 Phase 3 Exparel Injectable Product;Bupivacaine Hydrochloride
14 Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL) Terminated NCT02387697 Phase 2, Phase 3
15 NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients Completed NCT00809094 Phase 2 N-acetylcysteine (NAC);Placebo
16 LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction Completed NCT00887588 Phase 2 LCZ696;Valsartan;Placebo
17 The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis Completed NCT00630864 Phase 2 Fx-1006A
18 Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System Recruiting NCT03331380 Phase 1, Phase 2
19 A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism Recruiting NCT03108833 Phase 2 Recombinant Human Prourokinase;Alteplase
20 Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Recruiting NCT03466333 Phase 2 Enalapril Maleate;Placebo oral capsule
21 Preventive Approach to Congenital Heart Block With Hydroxychloroquine Recruiting NCT01379573 Phase 2 Hydroxychloroquine
22 Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) Recruiting NCT03525418 Phase 1, Phase 2
23 Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension Active, not recruiting NCT02951429 Phase 2 Pirfenidone;Placebo;Sildenafil
24 Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Active, not recruiting NCT03274076 Phase 1, Phase 2 Tofacitinib;Placebo Oral Tablet
25 Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction Not yet recruiting NCT03875183 Phase 2 INL1
26 A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis Terminated NCT01629667 Phase 2
27 Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™ Completed NCT02098200 Phase 1
28 Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease Completed NCT01895998 Phase 1 Albuterol
29 Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study Completed NCT01571037 Phase 1 Inhaled, nebulized, Milrinone;inhaled nebulized milrinone
30 Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers Completed NCT01673555 Phase 1 GSK1278863;Placebo
31 Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome Recruiting NCT02398604 Phase 1 Allo-hMSCs;Placebo
32 Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. Not yet recruiting NCT03406884 Phase 1 c-kit+ cells;Placebo
33 Study of GSK2586881 on Acute Hypoxia and Exercise Terminated NCT03000686 Phase 1
34 Ring Versus Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases Unknown status NCT02721524 Not Applicable
35 Behaviour of Tricuspid Valve Regurgitation in Volume and/or Pressure Loaded Right Heart Unknown status NCT01444222
36 The Impact of Right Ventricular Pacing on Tricuspid Regurgitation Unknown status NCT00419354
37 MitraClip for Severe TR Unknown status NCT02863549 Not Applicable
38 Prophylactic Tricuspid Valve Annuloplasty in Patients Undergoing Mitral Valve Surgery Unknown status NCT01580436 Not Applicable
39 Left Ventricular Pacing to Prevent Iatrogenic TR Pilot Study Unknown status NCT02314897 Not Applicable
40 Long-term Outcome After Isolated Tricuspid Valve Repair Unknown status NCT01537458
41 Reversibility by Sildenafil of Exercise-Induced Abnormal Right Ventricular Pressure Response in ASD and VSD-Operated Patients Unknown status NCT00772135 Not Applicable sildenafil citrate
42 Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ? Unknown status NCT01947257 Not Applicable
43 Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease Unknown status NCT00434902
44 Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation Completed NCT01246947 Not Applicable
45 Prognostic Value of Early Postoperative Right Ventricular Systolic Function in Patients With Isolated Severe Tricuspid Regurgitation Completed NCT01203137
46 The Comparison of Tricuspid Replacement and Repair in Patients With Combined Heart Valve Disease Completed NCT01246141
47 Prophylactic Tricuspid Annuloplasty During Mitral Valve Surgery Completed NCT03604484 Not Applicable
48 EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty Completed NCT01532921
49 Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial Completed NCT01585779
50 Serum Brain Natriuretic Peptide Levels and Pulmonary Hypertension in Pediatric Sickle Cell Patients Completed NCT01023451

Search NIH Clinical Center for Tricuspid Valve Insufficiency

Cochrane evidence based reviews: tricuspid valve insufficiency

Genetic Tests for Tricuspid Valve Insufficiency

Genetic tests related to Tricuspid Valve Insufficiency:

# Genetic test Affiliating Genes
1 Tricuspid Regurgitation 30

Anatomical Context for Tricuspid Valve Insufficiency

MalaCards organs/tissues related to Tricuspid Valve Insufficiency:

42
Heart, Brain, Testes, Bone Marrow, Small Intestine, Pituitary, Thyroid

Publications for Tricuspid Valve Insufficiency

Articles related to Tricuspid Valve Insufficiency:

(show top 50) (show all 1240)
# Title Authors Year
1
The Degree of Left Ventricular Hypoplasia Is Associated with Tricuspid Regurgitation Severity in Infants with Hypoplastic Left Heart Syndrome. ( 31065756 )
2019
2
Functional Tricuspid Regurgitation in Mitral Valve Disease. ( 30382771 )
2019
3
Tricuspid valve dysplasia and a patent foramen ovale resulting in severe tricuspid regurgitation and right-heart dilation in a Red Angus calf. ( 30797442 )
2019
4
Varicose veins of the lower extremity secondary to tricuspid regurgitation. ( 31075472 )
2019
5
Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. ( 30955879 )
2019
6
Is tricuspid regurgitation a prognostic interventional target or is it just an indicator of worst prognosis in heart failure patients? ( 30689817 )
2019
7
Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation Is Associated With Right Ventricular Reverse Remodeling in Patients With Right-Sided Heart Failure. ( 30660521 )
2019
8
Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. ( 30351406 )
2019
9
Predictors of residual tricuspid regurgitation after percutaneous closure of atrial septal defect. ( 29905827 )
2019
10
Prevalence and Significance of Tricuspid Regurgitation Post-Endocardial Lead Placement. ( 30219404 )
2019
11
Staged transcatheter valve repair via MitraClip XTR after Cardioband for tricuspid regurgitation. ( 30358806 )
2019
12
Prevalence, Echocardiographic Correlations, and Clinical Outcome of Tricuspid Regurgitation in Patients with Significant Left Ventricular Dysfunction. ( 30367857 )
2019
13
Incidence and predictors of moderate to severe tricuspid regurgitation after dual-chamber pacemaker implantation. ( 30417396 )
2019
14
Impact of concurrent tricuspid regurgitation on mortality after transcatheter aortic-valve implantation. ( 30474201 )
2019
15
Transcatheter tricuspid valve replacement for pacemaker-associated tricuspid regurgitation. ( 30530402 )
2019
16
Natural History of Functional Tricuspid Regurgitation: Implications of Quantitative Doppler Assessment. ( 30660536 )
2019
17
Quantifying Tricuspid Regurgitation Severity: A Comparison of Proximal Isovelocity Surface Area and Novel Quantitative Doppler Methods. ( 30660544 )
2019
18
Single-Center Experience With Catheter-Based Tricuspid Valve Replacement for Tricuspid Regurgitation: Procedural and Echocardiographic Findings. ( 30660546 )
2019
19
Tricuspid Regurgitation: Moderate (or More) Is a Burden for the Right Ventricle. ( 30660552 )
2019
20
Tricuspid regurgitation complicating SAPIEN 3 valve implantation in pulmonary position. ( 30684297 )
2019
21
A technique to prevent recurrence after the repair of pacemaker lead-induced tricuspid regurgitation. ( 30690469 )
2019
22
Tricuspid regurgitation and the right ventricle: risk stratification and timing of intervention. ( 30763278 )
2019
23
Design and evaluation of the crimping of a hooked self-expandable caval valve stent for the treatment of tricuspid regurgitation. ( 30773049 )
2019
24
Mid-term outcome of severe tricuspid regurgitation: are there any differences according to mechanism and severity? ( 30830219 )
2019
25
Modified band annuloplasty technique for functional tricuspid regurgitation repair in patients with grossly dilated annuli: The three-suture junctional continuous suture band annuloplasty technique. ( 30834563 )
2019
26
Imaging Assessment of Tricuspid Regurgitation Severity. ( 30846122 )
2019
27
Morphologic Types of Tricuspid Regurgitation: Characteristics and Prognostic Implications. ( 30846123 )
2019
28
Tricuspid Regurgitation: A Voyage of Discovery. ( 30846131 )
2019
29
Is the diameter of tricuspid annulus or functional tricuspid regurgitation the key parameter for performing 'prophylactic annuloplasty'? ( 30863866 )
2019
30
Prognostic Implications of Right Ventricular Free Wall Longitudinal Strain in Patients With Significant Functional Tricuspid Regurgitation. ( 30879327 )
2019
31
Recurrent tricuspid regurgitation due to valve migration after transcatheter tricuspid valve replacement. ( 30897616 )
2019
32
Acute and Short-Term Results of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation Using the MitraClip XTR System. ( 30898258 )
2019
33
Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates. ( 30907497 )
2019
34
Atrial functional tricuspid regurgitation: An underappreciated cause of secondary tricuspid regurgitation. ( 30919501 )
2019
35
Reverse Cardiac Remodeling After Transcatheter Treatment of Severe Tricuspid Regurgitation Using the Edge-to-Edge MitraClip Technique. ( 30927530 )
2019
36
Facial vein pulsation in severe tricuspid regurgitation. ( 30938317 )
2019
37
Tricuspid Regurgitation: Predicting the Need for Intervention, Procedural Success, and Recurrence of Disease. ( 30947904 )
2019
38
Cardiac Implantable Electronic Device Lead-Induced Tricuspid Regurgitation. ( 30947905 )
2019
39
Morphological Assessment of the Tricuspid Apparatus and Grading Regurgitation Severity in Patients With Functional Tricuspid Regurgitation: Thinking Outside the Box. ( 30947907 )
2019
40
Imaging Challenges in Tricuspid Regurgitation and Right Ventricular Failure. ( 30947910 )
2019
41
Analyses for Prevalence and Outcome of Tricuspid Regurgitation in China: An Echocardiography Study of 134,874 Patients. ( 30982035 )
2019
42
Epidural volume extension for caesarean section in a patient with severe pulmonary stenosis and moderate tricuspid regurgitation. ( 30988543 )
2019
43
6-Month Outcomes of Tricuspid Valve Reconstruction for Patients With Severe Tricuspid Regurgitation. ( 30999993 )
2019
44
Application of Transcatheter Repair to Tricuspid Regurgitation: Still Looking Through a Dark Glass. ( 30999994 )
2019
45
Multimodality and Fusion Imaging in Percutaneous Therapy of Tricuspid Regurgitation. ( 31007167 )
2019
46
Surgery is Not Associated with Improved Survival Compared to Medical Therapy in Isolated Severe Tricuspid Regurgitation. ( 31071413 )
2019
47
Characteristics and treatment strategies for severe tricuspid regurgitation. ( 31092546 )
2019
48
Outcomes After Surgical Treatment of Severe Tricuspid Regurgitation in a Contemporary Series. ( 29588136 )
2019
49
Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. ( 30121261 )
2019
50
Impact of concomitant tricuspid regurgitation on long-term outcomes in severe aortic stenosis. ( 30085068 )
2019

Variations for Tricuspid Valve Insufficiency

ClinVar genetic disease variations for Tricuspid Valve Insufficiency:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GATA4 NM_002052.4(GATA4): c.1273G> A (p.Asp425Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs56208331 GRCh37 Chromosome 8, 11615928: 11615928
2 GATA4 NM_002052.4(GATA4): c.1273G> A (p.Asp425Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs56208331 GRCh38 Chromosome 8, 11758419: 11758419
3 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh37 Chromosome 12, 112888168: 112888168
4 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 GRCh38 Chromosome 12, 112450364: 112450364
5 46;XX;ins(5;6)(p13;p24p25)dn Translocation Pathogenic
6 46;XX;inv(14)(q24.1q32.1)dn inversion Uncertain significance
7 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh38 Chromosome 16, 15724166: 15724166
8 MYH11 NM_001040113.1(MYH11): c.4381G> C (p.Asp1461His) single nucleotide variant Likely pathogenic rs1057518938 GRCh37 Chromosome 16, 15818023: 15818023

Expression for Tricuspid Valve Insufficiency

Search GEO for disease gene expression data for Tricuspid Valve Insufficiency.

Pathways for Tricuspid Valve Insufficiency

GO Terms for Tricuspid Valve Insufficiency

Cellular components related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 8.8 ALB ARSE FBN1

Biological processes related to Tricuspid Valve Insufficiency according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 8.8 ALB FBN1 PAPPA

Sources for Tricuspid Valve Insufficiency

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....